This activity is provided by Med Learning Group.
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2025 Med Learning Group. Built by Divigner. All Rights Reserved.
HD Visual Learning
HD Visual Learning
Animations
Case Study
VR Room Experience
Animations
Personalizing Treatment Across Cutaneous Malignancies
Shared Decision-Making in Oncology
Basal Cell Carcinoma and the Sonic Hedgehog Pathway
Pathogenesis of Basal Cell Carcinoma (BCC)
Hedgehog Pathway inhibitors in Locally Advanced and Metastatic Basal Cell Carcinoma (BCC)
Immunology and the Hedgehog Pathway in Basal Cell Carcinoma (BCC)
Depiction of the anti-cancer mechanism of action of Trop-2 antibody-drug conjugates in breast cancer
Shared Decision-Making in Oncology
Understanding Cell-free DNA (cfDNA)
Cancer Screening and Early Dection Test Accuracy
Understanding the Underlying Science of Current Cancer Screening
Discussing the Results of a Multicancer Early Detection Test
Personalizing Treatment Across Cutaneous Malignancies
Shared Decision-Making in Oncology
Immune Dysfunction in Cutaneous Squamous Cell Carcinoma (cSCC)
HER2 Expression in Cancer
Shared Decision-Making in Oncology
Gastric Cancer – Understanding anti-tumor effects and monitoring for adverse events
Angiogenesis Overview
Shared Decision-Making in Oncology
The Complement SystemÂ
PD1 and CTLA-4 Immune Checkpoints
Novel Immune Targets in Solid and Liquid Tumors
Personalizing Treatment Across Cutaneous Malignancies
Shared Decision-Making in Oncology
Shared Decision-Making in Oncology
The Role of Antibody Drug Conjugates in B-Cell Lymphomas
Understanding the Rationale for Bispecific Antibody Threapy in Relapsed/Refractory B-Cell Lymphomas
Personalizing Treatment Across Cutaneous Malignancies
Shared Decision-Making in Oncology
Reviewing the Pathophysiology of Melanoma
Developments of PD-L1 and LAG3 Combinations in Advanced Melanoma
Shared Decision-Making in Oncology
Mechanisms of Therapies in Later-Line Multiple Myeloma Management
Mechanisms of Resistance in Multiple Myeloma
Mechanisms of HER2 Activation in NSCLC
Adverse Events Associated With HER2-Directed ADCs for Advanced NSCLC: Presentation & Management
ICIs: Mechanistic Effects, Synergy and AE Management
Chemo ICI: Rationale for combined use of anti-PD(L)1 therapy and chemotherapy as a first-line treatment strategy in advanced NSCLC without targetable mutations
MOA: Evaluating the mechanisms of checkpoint inhibition in NSCLC and relevant adverse events
Shared Decision-Making in Oncology
Role of HER3 in EGFR-TKI resistance in Non-Small Cell Lung Cancer (NSCLC)
TROP2 Cell-Aurface Antigen in Tumors and Tumorgenesis
Frequent adverse events associated with Trop-2 antibody-drug conjugate therapy
MOAs of HER2-directed ADCs for HER2-expressing solid tumors
Development of AEs associated with the use of ADCs
Case Study
Management of Recurrent Stage 2 cSCC and Rationale for Treatment
Management Pearls for Treatment of Multiple Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Treatment Strategies for Relapsed/Refractory Multiple Myeloma
NSCLC – Shared Decision Making Case Study
VR Room Experience
The ENCOMPASS Experience: Integrating Multidisciplinary Care and Immunotherapy for Durable, Long-Term Outcomes in Non-Melanoma Skin Cancer
Virtual Booth
The ENCOMPASS Experience: Employing Immunotherapy, Shared-Decision-Making and Multidisciplinary Care in the Mangement of Patients with Advanced Melanoma
Virtual Booth
The ENCOMPASS Experience: The Management of Relapsed/Refractory Non-Hodgkins Lymphoma with Bispecific Antibodies
Virtual Booth
Personalized Medicine for Metastatic Non-Small Cell Lung Cancer: Leveraging Immune Competence
Virtual Booth
Evaluating the Latest Data in NHL: Contemporary Considerations With Novel Bispecific Antibodies with Dr. Amitkumar Mehta
Virtual Booth
The ENCOMPASS Experience: Incorporating Bispecific Antibodies into the Care of Patients with Relapsed/Refractory Multiple Myeloma with an Emphasis on Managing Potential Adverse Events
Virtual Booth
Improving Outcomes for Steroid-Resistant Chronic Graft vs Host Disease: SECOND-LINE OPTIONS AND BEYOND *Supported by an independent medical education grant from Sanofi US.
Virtual Booth